Xijing Hospital of Digestive Diseases
Xi'an, Shaanxi, 710032, China
NCT Number: NCT01760070
By combining injection and dissection capability together, O-type Hybrid knife could possibly shorten the endoscopic submucosal dissection procedure for upper gastrointestinal neoplasms.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Xi'an, Shaanxi, 710032, China
Endoscopic submucosal dissection (ESD) has been accepted as an minimal invasive alternative to surgery for localized early upper gastrointestinal neoplasms recently. However, the procedure remains to be technically challenging and time consuming. Many modified methods or newly developed devices were developed to simplify the procedure. A new insulated tip dissecting knife (O-type Hybrid knife) has been recently developed with both injection and lateral cutting capability. The aim of this study was to investigate whether ESD procedure could be shortened with this new device.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use Hybrid knife in ESD procedure
Use IT knife in ESD procedure.
Time frame: up to 1 day
The time to finish the whole ESD procedure.
Time frame: up to 1 day
The time for submucosal dissection of ESD
Time frame: up to 7 day
The perforation rate of ESD during and after procedure.
Time frame: up to 7 days
The bleeding rate of ESD during and after procedure.
Xijing Hospital of Digestive Diseases
Other
Comparison of O-type Hybrid Knife and IT Knife in Endoscopic Submucosal Dissection for Upper Gastrointestinal Neoplasms: a Prospective Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04028479
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Idaho Falls, Idaho, United States
View Trial DetailsNCT03384511
Adnexal Diseases, Breast Cancer
Jinan, Shandong, China
View Trial DetailsNCT01246960
Digestive System Diseases, Digestive System Neoplasms
Anchorage, Alaska, United States
View Trial DetailsNCT07578571
Breast Cancer, Breast Diseases
Sarasota, Florida, United States
View Trial Details